BNGO vs. HBIO, SEER, AKYA, PRE, RPID, AXDX, OMIC, ASTC, TLIS, and HLTH
Should you be buying Bionano Genomics stock or one of its competitors? The main competitors of Bionano Genomics include Harvard Bioscience (HBIO), Seer (SEER), Akoya Biosciences (AKYA), Prenetics Global (PRE), Rapid Micro Biosystems (RPID), Accelerate Diagnostics (AXDX), Singular Genomics Systems (OMIC), Astrotech (ASTC), Talis Biomedical (TLIS), and Cue Health (HLTH). These companies are all part of the "analytical instruments" industry.
Bionano Genomics (NASDAQ:BNGO) and Harvard Bioscience (NASDAQ:HBIO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, community ranking, risk, earnings, dividends and valuation.
Bionano Genomics has a beta of 2.4, indicating that its share price is 140% more volatile than the S&P 500. Comparatively, Harvard Bioscience has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500.
Bionano Genomics currently has a consensus price target of $4.00, indicating a potential upside of 313.22%. Given Bionano Genomics' higher possible upside, analysts clearly believe Bionano Genomics is more favorable than Harvard Bioscience.
Harvard Bioscience has higher revenue and earnings than Bionano Genomics. Harvard Bioscience is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.
Harvard Bioscience received 206 more outperform votes than Bionano Genomics when rated by MarketBeat users. Likewise, 72.02% of users gave Harvard Bioscience an outperform vote while only 64.80% of users gave Bionano Genomics an outperform vote.
Harvard Bioscience has a net margin of -8.18% compared to Bionano Genomics' net margin of -605.26%. Harvard Bioscience's return on equity of 0.26% beat Bionano Genomics' return on equity.
11.4% of Bionano Genomics shares are owned by institutional investors. Comparatively, 80.9% of Harvard Bioscience shares are owned by institutional investors. 1.7% of Bionano Genomics shares are owned by insiders. Comparatively, 9.0% of Harvard Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, Harvard Bioscience had 11 more articles in the media than Bionano Genomics. MarketBeat recorded 14 mentions for Harvard Bioscience and 3 mentions for Bionano Genomics. Bionano Genomics' average media sentiment score of 1.22 beat Harvard Bioscience's score of 0.23 indicating that Bionano Genomics is being referred to more favorably in the media.
Summary
Harvard Bioscience beats Bionano Genomics on 11 of the 17 factors compared between the two stocks.
Get Bionano Genomics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BNGO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BNGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bionano Genomics Competitors List
Related Companies and Tools
